Overview

A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer

Status:
Recruiting

Trial end date:
2025-06-16

Target enrollment:

Participant gender:

Summary

This is an international, multisite, open-label, Phase 1b/2 study, to confirm safety and efficacy of samuraciclib in combination with elacestrant in adult participants with metastatic or locally advanced Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor (HER)2-negative breast cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Carrick Therapeutics Limited

Collaborator:

Berlin-Chemie AG Menarini Group